Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efatutazone in Previously Treated Myxoid Liposarcoma
NCT02249949Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2015
- Primary completion
- Oct 2018
- Countries
- 1
- Sponsor
- Cancer and Leukemia Group B
- Modality
- Orthosteric Ligands
- Drugs
- efatutazone
- Conditions
- myxoid liposarcoma (MLPS)
01
Overview
Phase 2, open-label, single-arm trial of efatutazone in myxoid liposarcoma (MLPS), sponsored by Cancer and Leukemia Group B. Primary endpoint: Confirmed Overall Response Rate at 24 weeks. Started Feb 2015; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Efatutazone Arm
Patients receive efatutazone dihydrochloride PO BID continuously.
03
Endpoints
Primary
Confirmed Overall Response Rate
Secondary
Progression Free Survival
Overall Survival
Incidence of Grade 3+ Adverse Events
Beyond the preview
Go deeper on NCT02249949.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249949.